Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin Alfa in Anemic Low/Int-1 Risk MDS
NCT01362140Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2011
- Primary completion
- Feb 2015
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 9
01
Overview
A Phase 3 trial of darbepoetin alfa in myelodysplastic syndrome (MDS), sponsored by Amgen. Started Dec 2011; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01362140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01362140.